INTRODUTION
Over the past decade, there has been a significant decrease in the rate that new anticancer drug candidates are being translated into effective therapies in the clinic. In particular, there has been a worrying rise in late-stage attrition in phase 2 and phase 3 [1] . Currently, the two single most important reasons for this attrition, each of which account for 30% of failures are (i) lack of efficacy and (ii) clinical safety or toxicology. These late-stage attrition rates are at the heart of much of the relative decline in productivity of the pharmaceutical industry resulting in significant financial setbacks. In addition, because many patents on the current generation of marketed drugs will expire from 2010 onward, pharmaceutical companies will face the first fall in revenue in four decades.
With advances in human genome biology and the advent of personalized medicine, new opportunities for the discovery of drug targets are arising. The fundamental challenge of anticancer therapy is the need for agents that eliminate cancer cells with a therapeutic index that is safely tolerated by the patient. However, the selection of suitable anticancer drug targets is complicated by the fact that over 100 genes have been shown to be involved in the disease, rendering it necessary to develop multiple therapies.
In addition, the cell shows a remarkable degree of robustness, in which impairment of the functions of some genes by mutation or drug targeting can be rescued by the action of other genes. For example, using genetic engineering techniques to knock out the function of over 40% of the approximately 6000 yeast genes one-by-one has little effect on cell growth in rich medium [2, 3] .
The transcription factor P53 is encoded by a tumor suppressor gene that can arrest the cell cycle and facilitate apoptosis. P53 functions as a sensor of upstream signals that reflect DNA-damage and cellular stresses such as hypoxia, providing protection against tumor growth, and the action of oncogenes (Myc, Ras, E1A, ß-catenin) [4, 5] . These signals activate latent p53 by enhancing its DNA-binding activity and increasing its stability, resulting in increased levels of 10-100x of the protein. Since enhanced levels of p53 lead to cell cycle-arrest and apoptosis, it is of critical importance that normal cells keep their p53 levels low. This can be accomplished by destabilization of P53 by interaction with the protein Mdm2. Interaction with Mdm2 causes export of P53 from the nucleus to the cytoplasm where it is targeted for proteosomal degradation by interaction with a P53-specific E3 ubiquitin [6] . The gene encoding Mdm2 is activated by P53 but at a time that is relatively late in the cell cycle providing a window of time where P53 can function.
P53 has been considered a suitable target for anticancer therapies because of its widespread implication in about 50% of all cases of cancer [7] [8] [9] . It is also a node protein with extensive interaction partners (a hub) and high turnover rate [10] . As such, its function may not easily be replaced by other proteins (knockout inviable) [10] . Several strategies have been explored in attempts to stabilize P53 by preventing or diminishing its interaction with Mdm2 [11] [12] [13] [14] [15] [16] [17] [18] . The long term objective is to improve the efficacy of P53 to promote cell apoptosis in cancer cells.
Given the promise of this approach and the substantial body of mathematical modeling and experimental evidence describing the cellular oscillations of the P53-Mdm2 pair, we decided to explore the use of CellDesigner, as a tool for evaluating the network consequences of eliminating the interaction of Mdm2 with P53. CellDesigner can visualize, model and simulate biochemical networks and can integrate with existing databases such as KEGG, PubMed, BioModels [19] .
METHODS

Systems parameters
The parameters that describe the initial states and oscillatory nature of the p53-Mdm2 interaction in the normal cell were obtained by combining information from several sources [20] [21] [22] [23] . These parameters allow the partial differential equations that govern the system to be derived:
Equations 1 describes the negative feedback loop (defined as x) for P53 in which its activity decreases with time according to the mass-action binding of Mdm2 to P53 resulting in P53 ubiquitination and subsequent proteasomal degradation. Equation 2 describes the transcriptional activity of p53 (defined as y), depending on an initial value and a production rate that decreases with time as Mdm2 activity increases. Equation 3 describes the transcriptional activity of Mdm2 (yo) which decreases from an initial value because of the negative feedback loop imposed by parameters described in the second equation.
For these equations, the variables are derived from [21] 20) . The other parameters are: αk is the rate of Mdm2-independent degradation of P53 and the P53-dependent Mdm2 production rate (0); αy is the Mdm2 degradation rate (0.8); βx is the P53 production rate (0.9); βy is the P53-dependent MDM2 production rate (1.1); αo is the maturation rate (0); k is the P53 threshold for degradation by MDM2 (0.0001) and ξ is equal to 1. On addition of a drug that completely eliminates the P53-Mdm2 interaction, factors are added to the x and yo equations, where δ is the drug concentration (0.17 arbitrary units).
Pathways and Use of CellDesigner
Pathways describing the interaction of P53 with Mdm2 were uploaded from KEGG [24] into CellDesigner using the intuitive interface comprised of graphical notation, model description and an application integration environment as described [19, [25] [26] [27] .
RESULTS
Two network models for the interaction of P53 and Mdm2 were generated by CellDesigner. The first network illustrates the negative feedback loop that models the experimentally observed time-delayed oscillatory nature of both P53 and Mdm2 (Fig. 1A) . The second network introduces a drug-induced inhibition of the interaction between P53 and Mdm2 that in turn impedes the ubiquitination of P53 and its subsequent degradation by proteosomes (Fig. 1B) . The drug is hypothetical and is assumed to cause significant inhibition of the P53/Mdm2 interaction.
Using parameters described in Methods and the networks shown in Fig. 1 , CellDesigner was used to predict fluctuations of P53 and Mdm2 for 400 min in normal cells ( Fig. 2A) and for 200 min in cells with the drug application (Fig. 2B) . The application successfully predicted the time-delayed, oscillatory profiles of the interacting partners in the normal cell with the characteristic 20 min periodicity of fluctuation ( Fig. 2A) and predicted a damping out of both P54 and Mdm4 after the addition of the drug (Fig. 2B ) that has been observed in mathematical models [29, 30] . 
DISCUSSION
The time-delayed, oscillatory behavior of P53 and Mdm2 in the normal cell has been observed experimentally [29] and has been modeled theoretically [28, [30] [31] [32] [33] . In addition, mathematical models have been developed that predict damping-out of concentrations of P53 following the perturbation of the interaction of P54 with Mdm2 via a naturally occurring mutation [38] or after treatment with the small molecule inhibitor Nutlin-3 [36] . The problem with these theoretical models is that they are essentially "static". CellDesigner is also able to successfully model the behavior of P54 and Mdm2 in the normal cell (Figs. 1A and 2A ) and can also predict damping out when a theoretical drug that prevents P54/Mdm2 interaction is introduced into the system (Figs 1B and 2B) . However, in contrast to the previous models, CellDesigner integrates pathway visualization with analysis using Systems Biology Markup Language [38] , providing a more dynamic model of cellular processes through the incorporation of gene expression data, subcellular localization information, time-dependent behavior, chemical reactions, kinetic equations etc. a one stop shopping environment. Also, because CellDesigner is open source, custom designed plug-ins can be added when required. CellDesigner has been used to predict suitable drug targets for for methicillin-resistant bacteria [39] , but this is the first time that it has been used to examine anti-cancer targets. Because it is open source and manageable in a user-friendly fashion, we have found CellDesigner to be an excellent aid for teaching systems biology at the undergraduate and graduate level.
Other open source services similar to CellDesigner include PathwayStudio [40] , Cytoscape [41] , VisANT [42] , BiologicalNetworks [43] and Teranode Pathway Analytics (available at www.teranode.com/). As increasing abundance of experimental data from high-throughput experimental biology becomes available and as the cost, efficiency and accuracy of this data improves, greater emphasis will be put on systems biology applications such as Celldesigner and others for connecting vast amounts of data and but also capturing usable knowledge in the form of biologically valid relations that research scientists can apply.
The modeling of the P53/Mdm2 interaction network presented here represents a simplistic first step for evaluating anticancer drug targets by CellDesigner. But it should serve as the starting point for several interesting lines of further inquiry including the evaluation of the interactions of P53 with Akt [44] , p14ARF and ATM [20] , Pten and Pip3 [45] and other members of its interactome. This information needs to be explored in order to provide a more comprehensive understanding of the potential of the P53/Mdm2 interaction as a anticancer drug target.
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